Fujifilm Holdings Corp. said Friday it is on course to supply the flu drug Avigan for 2 million COVID-19 patients by next March, meeting a target set by the government to ramp up production of the potential but yet unapproved coronavirus treatment.
"We plan to complete delivery of the drug for 2 million people within fiscal 2020 to the government," said Fujifilm Senior Vice President Junji Okada in an online news conference on its earnings for the year ended March.
"The drug has received much interest from foreign countries," Okada said of Avigan, also known as favipiravir. The drug was developed by its unit Fujifilm Toyama Chemical Co.
The government has earmarked about ¥13.9 billion ($129 million) in an extra budget for fiscal 2020 to triple the national stockpile of Avigan, enough to treat 2 million people.
Due to the government's request, Fujifilm has been boosting production of the drug since April.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
PHOTO GALLERY (CLICK TO ENLARGE)
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.